Feb 13 (Reuters) - Softbank-backed (9434.T), opens new tab genetic test maker Invitae (NVTA.PK), opens new tab said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Genetic test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported onMonday, ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...